fluoro-Dapagliflozin argyl-PEG4-alcohol 4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl}-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide

4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl}-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide

L-692585 (100 nM) significantly increases the number and size of plaques

an enzyme important in the formation of (1→3)-β-D-glucan

Geraniin is a TNF-α releasing inhibitor with numerous activities including anticancer

fluoro-Dapagliflozin argyl-PEG4-alcohol 4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl}-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamideKi: 5. 3 and 330 nM for SGLT2 and SGLT1, respectively fluoro Dapagliflozin is a selective sodium glucose cotransporter (SGLT) inhibitor. Human Na(+) D glucose cotransporter (hSGLT) inhibitors constitute the newest class of diabetes drugs, blocking up to in vivo 50% of renal glucose reabsorption. In vitro: Dapagliflozin and fluoro dapagliflozin could block glucose transport and glucose coupled currents with around 100 fold specificity for hSGLT2 over